Shares of Mylan (MYL) were higher Monday after the drugmaker announced it will begin offering a generic version of its' EpiPen for $300, representing a 50 percent discount from current prices. Mylan CEO Heather Bresch said Monday, 'We understand the deep frustration and concerns associated with the cost of EpiPen to the patient, and have always shared the public's desire to ensure that this important product be accessible to anyone who needs it.' Mylan shares are down sharply since last week when the senate called attention to steep price hikes of the epipen treatment over the past several years.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.